- Trial phase
- Filed/NDA under FDA review
- Time to market
- If the FDA accepts the NDA for filing (expected mid-November 2026), a standard 10-month review would set a PDUFA target action date around mid-2027. The drug could potentially launch in the second half of 2027 if approved.
- Why 7/10
- The next hard catalyst is the FDA's 60-day filing acceptance decision on the azetukalner NDA (submitted Sept 17, 2026), expected around mid-November 2026. If accepted, a PDUFA date would be set. Azetukalner is Xenon's only late-stage asset and essentially the entire company value driver, but the psychiatry program pause has created significant overhang, capping the impact score.
The next near-term catalyst is the FDA's 60-day filing acceptance decision on the azetukalner NDA, expected around mid-November 2026. If accepted, a PDUFA date (likely standard review, ~10 months, pointing to mid-2027) would be set. The Q3 2026 earnings call on Nov 9 may also provide updates on the psychiatry program pause and the X-TOLE3/X-ACKT epilepsy trials. The psychiatry safety overhang and the stock's 46% decline from its 52-week high mean the FDA filing acceptance and any clarity on the depression program restart timeline are the key swing factors.
Price Chart
Executive Summary
Azetukalner (XEN1101) is a novel KV7 potassium channel opener being developed by Xenon Pharmaceuticals (XENE) for epilepsy and psychiatric disorders. The drug produced strong Phase 3 data in focal onset seizures (53.2% median seizure reduction at 25mg vs 10.4% placebo, p<0.0001), and an NDA was submitted to the FDA on September 17, 2026. However, the company simultaneously paused enrollment in Phase 3 depression trials after neuropsychiatric adverse events including psychosis emerged, causing the stock to crash 30% in a single day. The stock now trades at $39.19, well off its 52-week high of $72.66, with analyst consensus at Strong Buy and a mean price target of $71.75. The next catalyst is the FDA's 60-day filing acceptance decision, expected around mid-November 2026.
How It Works
Azetukalner is a KV7 potassium channel opener. It works by opening specific potassium channels on the surface of neurons, which helps stabilize the electrical activity of brain cells and makes them less likely to fire abnormally. This dampens the excessive, synchronized electrical activity that causes seizures. It is taken as a once-daily oral pill.
Trial Status
The Phase 3 X-TOLE2 trial (n=380) in focal onset seizures met its primary endpoint with high statistical significance. An NDA was submitted to the FDA on September 17, 2026. Two additional Phase 3 epilepsy trials (X-TOLE3 in focal seizures, X-ACKT in primary generalized tonic-clonic seizures) continue to enroll. Three Phase 3 psychiatry trials (X-NOVA2 in MDD, X-CEED in bipolar depression) had new enrollment paused in September 2026 due to neuropsychiatric adverse events; existing patients continue in the studies.
The Two-Sided Case
Upcoming Catalysts
- FDA 60-day filing acceptance decision on the azetukalner NDA (expected mid-November 2026)
- Q3 2026 earnings call on November 9, 2026 (business update, psychiatry program update)
- Potential PDUFA date assignment if NDA is accepted for filing
- X-TOLE3 and X-ACKT Phase 3 epilepsy trial enrollment completion updates
- X-NOVA2 MDD topline data (previously expected H1 2027, but timeline uncertain due to enrollment pause)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Xenon Pharmaceuticals Inc. PRESS-RELEASE XENE ·Originating report